Match!
Olufunmilayo I. Olopade
University of Chicago
CancerBreast cancerGeneticsMedicineBiology
611Publications
81H-index
31.7kCitations
What is this?
Publications 622
Newest
#1Liese C.C. Pruitt (UofU: University of Utah)H-Index: 4
#2Stella Odedina (UI: University of Ibadan)H-Index: 2
Last. Oladosu Ojengbede (UI: University of Ibadan)H-Index: 17
view all 11 authors...
PURPOSEBreast cancer is the most common cancer among women, and in low- to middle-income countries late-stage diagnosis contributes to significant mortality. Previous research at the University Col...
Source
#1Xin Yang (University of Cambridge)H-Index: 2
#2Goska Leslie (University of Cambridge)H-Index: 5
Last. Marc Tischkowitz (University of Cambridge)H-Index: 39
view all 119 authors...
PURPOSETo estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germl...
5 CitationsSource
#1Jim Leng (U of C: University of Chicago)
#2Atara Ntekim (UI: University of Ibadan)H-Index: 2
Last. Olufunmilayo I. Olopade (U of C: University of Chicago)H-Index: 81
view all 6 authors...
PURPOSEIn low- and middle-income countries, there has been an exponential increase in cancer incidence. According to the International Atomic Energy Agency, the biggest gap in radiotherapy availabi...
Source
#1Masaya Hattori (U of C: University of Chicago)
#2Dezheng Huo (U of C: University of Chicago)H-Index: 52
view all 12 authors...
Background: Neoadjuvant therapy is currently standard of care for patients with HER2-positive (HER2+) breast cancer. Patients with residual disease after neoadjuvant therapy have a higher risk of metastatic recurrence compared to patients achieving pathologic complete response (pCR). While both primary breast cancer and residual disease may harbor cancer cell subpopulations with high metastatic potential, residual disease after neoadjuvant targeted therapy may include larger subpopulations of th...
Source
#1Mandy Che (UCSF: University of California, San Francisco)
#2Allison Stover Fiscallini (UCSF: University of California, San Francisco)
Last. Barry Tong (UCSF: University of California, San Francisco)
view all 42 authors...
Background: WISDOM is a 100,000 healthy women preference-tolerant, pragmatic study comparing traditional annual screening to personalized risk-based breast screening. The novelty of WISDOM personalized screening is the integration of previously validated genetic and clinical risk factors (age, family history, breast biopsy results, ethnicity, mammographic density) into a single risk assessment model that directs the starting age, timing, and frequency of screening. The goal of WISDOM is to deter...
Source
#1Babatunde O. Adedokun (U of C: University of Chicago)H-Index: 13
#2Yonglan Zheng (U of C: University of Chicago)H-Index: 21
Last. Dezheng Huo (U of C: University of Chicago)H-Index: 52
view all 13 authors...
Background: Sub-Saharan Africa (SSA) has a high proportion of premenopausal hormone receptor negative breast cancer. Previous studies reported a strikingly high prevalence of germline mutations in BRCA1 and BRCA2 among Nigerian breast cancer patients. It is unknown if this exists in other SSA countries. Methods: Breast cancer cases, unselected for age at diagnosis and family history, were recruited from tertiary hospitals in Kampala, Uganda and Yaounde, Cameroon. Controls were women without brea...
Source
#1Gu Xiao (Hunter College)H-Index: 6
#2Devon Lundine (CUNY: City University of New York)
Last. Jill Bargonetti (CUNY: City University of New York)H-Index: 25
view all 12 authors...
Over 80% of Triple Negative Breast Cancers (TNBC) express mutant p53 (mtp53) and some contain oncogenic gain-of-function (GOF) p53. We previously reported that GOF mtp53 R273H upregulates the chromatin association of Mini Chromosome Maintenance (MCM) proteins MCM2-7 and Poly-ADP-Ribose Polymerase (PARP) and named this the mtp53-PARP-MCM axis. In this study we dissected the function and association between mtp53 and PARP using a number of different cell lines, patient-derived xenografts, tissue m...
Source
#1Tamara Hamlish (UIUC: University of Illinois at Urbana–Champaign)
#2Li Liu (UIUC: University of Illinois at Urbana–Champaign)
Last. Susan Hong (UIUC: University of Illinois at Urbana–Champaign)
view all 9 authors...
Background Few studies have examined cancer care coordination at federally qualified health centers (FHQCs). The Commission on Cancer’s (CoC) standard 3.3, i.e., treatment summaries and survivorship care plans (TS-SCPs), is aimed at improving communication between cancer specialists and primary care providers (PCPs) across all healthcare systems. Whether this will improve care at FQHCs is unclear. We sought to understand breast cancer care coordination at FQHCs before the stepwise implementation...
Source
#1Shengfeng Wang (PKU: Peking University)H-Index: 4
#2Jason J. Pitt (U of C: University of Chicago)H-Index: 10
Last. Olufunmilayo I. Olopade (U of C: University of Chicago)H-Index: 81
view all 22 authors...
Source
#1Xia Jiang (KI: Karolinska Institutet)H-Index: 6
#1Xia Jiang (KI: Karolinska Institutet)H-Index: 12
Last. Sara Lindstroem (UW: University of Washington)H-Index: 46
view all 333 authors...
Source
12345678910